Where can I find news about BMRN?

The latest headlines, third-party analysis, and SEC filings for BioMarin Pharmaceutical Inc. (BMRN) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are BMRN's SEC filings?

BioMarin Pharmaceutical Inc. (BMRN)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are BMRN's earnings call transcripts?

Full earnings call transcripts for BioMarin Pharmaceutical Inc. (BMRN) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

BMRN

BioMarin Pharmaceutical Inc.

NASDAQ·Biotechnology · Healthcare

$64.41$0.22−0.34%

After hours·$64.41+0.00%

Market cap$12.45B·Market closed·Sep 9 8:00 PM UTC

News & Analysis

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
seekingalpha.comSep 9, 2026 · 7:17 PM
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demonstrated statistically significant improvements across multiple measures of growth, including annualized growth velocity, standing height, height Z-score and arm span BioMarin recently submitted a supplemental New Drug Application (sNDA) to the FDA to support expanding treatment with VOXZOGO to include children with hypochondroplasia SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting.
prnewswire.comSep 9, 2026 · 9:05 AM
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
zacks.comSep 3, 2026 · 1:31 PM
BioMarin to Participate in Upcoming Investor Conferences
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST SAN RAFAEL, Calif., Sept. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.
prnewswire.comSep 2, 2026 · 9:00 AM
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
zacks.comSep 1, 2026 · 12:01 PM
BioMarin Announces Close of the Alesta Therapeutics Acquisition
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics.
prnewswire.comSep 1, 2026 · 9:05 AM
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel.
benzinga.comAug 31, 2026 · 8:06 AM
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and
gurufocus.comAug 31, 2026 · 3:00 AM

SEC Filings

8-K
Sep 1, 2026View on SEC
8-K
Aug 31, 2026View on SEC
8-K
Aug 18, 2026View on SEC
S-8
Aug 6, 2026View on SEC
10-Q
Aug 6, 2026View on SEC
8-K
Aug 6, 2026View on SEC

Frequently Asked Questions About BMRN

Where can I find news about BMRN?: The latest headlines, third-party analysis, and SEC filings for BioMarin Pharmaceutical Inc. (BMRN) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are BMRN's SEC filings?: BioMarin Pharmaceutical Inc. (BMRN)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are BMRN's earnings call transcripts?: Full earnings call transcripts for BioMarin Pharmaceutical Inc. (BMRN) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

BioMarin Pharmaceutical Inc.

Frequently Asked Questions About BMRN

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BioMarin to Participate in Upcoming Investor Conferences

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

BioMarin Announces Close of the Alesta Therapeutics Acquisition

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

Frequently Asked Questions About BMRN

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BioMarin to Participate in Upcoming Investor Conferences

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

BioMarin Announces Close of the Alesta Therapeutics Acquisition

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea